Each of the approved IFNb preparations for relapsing forms of MS has demonstrated efficacy as measured by reduced relapse rates, delayed progression of disability and reduced number of lesions detected by magnetic resonance imaging (MRI) in pivotal phase III clinical trials [1]. Here, IFNB1 is linked to myeloid sarcoma.